21 completed, 1 enrolling by invitation, 1 recruiting, 1 terminated. 12 Not applicable, 5 Phase 1, 4 Phase 2, 2 Phase 3, 2 Phase 4.
Follow Incretins: new trials by email Literature Review of Incretins trials Research Report on Incretins
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals Glucose-dependent Insulinotropic Polypeptide (GIP), GLP-1 (7-36) amide, Apomorphine Injectable Solution - Emesis | Not applicable | Enrolling by invitation | University of Copenhagen | 14 | 2026-05-19 | 2026-07-07 |
| A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese Glucose-dependent Insulinotropic Polypeptide (GIP), Cagrilintide, Placebo GIP - Overweight, Obese | Phase 1 | Recruiting | Novo Nordisk A/S | 100 | 2026-02-09 | 2026-04-13 |
| Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA) Glucose-dependent Insulinotropic Polypeptide (GIP) - Bone Disease, Metabolic, Diabetes Mellitus, Type 2 | Not applicable | Completed | Esbjerg Hospital - University Hospital of Southern Denmark | 13 | 2025-11-10 | 2026-10-01 |
| The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes Glucose-dependent Insulinotropic Polypeptide (GIP), alanine, Saline (NaCl 0,9 %) (placebo) - Type 1 Diabetes | Not applicable | Completed | Asger Lund, MD | 10 | 2025-01-01 | 2026-04-29 |
| The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes Semaglutide 1.34 MG/ML [Ozempic], Glucose-dependent insulinotropic polypeptide (GIP), Semaglutide 1.34 mg/ml placebo - Type 2 Diabetes, Obesity | Not applicable | Completed | Asger Lund, MD | 61 | 2022-01-27 | 2025-03-14 |
| Effects of Gut Peptides on Bone Remodeling Glucagon-Like Peptide-2 (GLP-2), Glucose-dependent insulinotropic polypeptide (GIP), GLP-2+GIP - Healthy | Not applicable | Completed | University of Copenhagen | 10 | 2018-06-01 | 2021-01-20 |
| Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics Incretins - Diabetes, Coronary Artery Disease | Phase 4 | Completed | University of Campania Luigi Vanvitelli | 150 | 2017-09-20 | 2026-04-23 |
| SGLT2i and Incretin and CRTd. Incretin Effect, Cardiac Resynchronization therapy defibrillator device, SGLT-2 inhibitor - Type 2 Diabetes Mellitus, Heart Failure | Phase 4 | Completed | University of Campania Luigi Vanvitelli | 500 | 2017-09-01 | 2025-06-25 |
| The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea Glimepiride 1Mg Tablet, Glucagon-like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide - Maturity-Onset Diabetes of the Young, Type 3 | Not applicable | Completed | University Hospital, Gentofte, Copenhagen | 20 | 2017-03-08 | 2019-06-27 |
| STEMI and Incretins Treatment PCI and DES stenting, Incretins - STEMI, Coronary Artery Disease | Completed | University of Campania Luigi Vanvitelli | 900 | 2017-01-01 | 2017-10-19 | |
| Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients Exenatide, Insulin - Quality of Life | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 64 | 2015-05-01 | 2021-03-09 |
| Exenatide for Stress Hyperglycemia Exenatide, Insulin - Stress Hyperglycemia | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire de Besancon | 110 | 2015-01-01 | 2017-10-06 |
| Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle GLP-1, Insulin Actrapid, Oral amino acids - Sarcopenia | Not applicable | Completed | University of Nottingham | 40 | 2014-11-01 | 2018-05-02 |
| Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes GIP, GLP-1, Saline - Type 1 Diabetes Mellitus | Not applicable | Completed | Mikkel Christensen | 10 | 2012-11-17 | 2017-06-23 |
| GIP Effects at Insulin Induced Hypoglycemia in Patients With Type 2 Diabetes Glucose-dependent Insulinotropic polypeptide, saline - Type 2 Diabetes Mellitus | Early Phase 1 | Completed | Mikkel Christensen | 12 | 2011-05-01 | 2013-04-02 |
| Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates glucagon like peptide-1, glucose control - Type 2 Diabetes | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 20 | 2010-08-12 | 2024-02-28 |
| Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer? glucose-dependent insulinotropic polypeptide, Placebo - Diabetes Mellitus | Phase 1 / Phase 2 | Completed | University Hospital, Gentofte, Copenhagen | 30 | 2009-12-01 | 2015-07-14 |
| Xenin-25: Novel Regulator of Insulin Secretion and Beta-cell Function Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Washington University School of Medicine | 38 | 2009-10-01 | 2014-07-22 |
| Study of the Effects of Xenin-25 in Humans With and Without Type 2 Diabetes Mellitus Placebo, Glucose-dependent Insulinotropic Polypeptide (GIP), Xenin-25 - Diabetes | Phase 1 | Completed | Washington University School of Medicine | 40 | 2008-12-01 | 2018-05-03 |
| Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome GLP-1 infusion - Metabolic Syndrome | Not applicable | Completed | University of Rome Tor Vergata | 20 | 2008-11-01 | 2013-12-11 |
Showing 20 of 24. Sign in to see all of them.
Diabetes Mellitus, Type 2 (8) · Diabetes Mellitus (6) · Insulin Resistance (5) · Obesity (4) · Coronary Artery Disease (2) · Diabetes Mellitus, Type 1 (2) · Metabolic Syndrome (2) · Angina, Unstable (1) · Bone Diseases, Metabolic (1) · Heart Failure (1) · Maturity-Onset Diabetes of the Young, Type 3 (1) · Nausea (1) · Overnutrition (1) · Overweight (1) · ST Elevation Myocardial Infarction (1)
University of Campania Luigi Vanvitelli (3) · Asger Lund, MD (2) · Centre Hospitalier Universitaire de Besancon (2) · Hvidovre University Hospital (2) · Mikkel Christensen (2) · University Hospital, Gentofte, Copenhagen (2) · University of Copenhagen (2) · Washington University School of Medicine (2) · Albert Einstein College of Medicine (1) · Esbjerg Hospital - University Hospital of Southern Denmark (1) · German Institute of Human Nutrition (1) · Herlev Hospital (1) · Novo Nordisk A/S (1) · University of Nottingham (1) · University of Rome Tor Vergata (1)
Denmark (11) · Italy (4) · United States (3) · France (2) · United Kingdom (2)
Burton Wice, PhD (2) · Dominic Reeds, MD (2) · Filip K Knop, MD PhD (2) · Daniel T Stein, MD (1) · Guillaume Besch, MD (1) · Iskandar Idris, DM, FRCP (1) · Manfredi Tesauro, MD (1) · Mikkel Christensen, MD (1) · Philip Atherton, PhD (1)
PMID 31665480, PMID 19037628, PMID 22522617, PMID 23069838, PMID 24183983, PMID 24356886, PMID 24423311, PMID 25538323, PMID 25994074, PMID 29099978, PMID 30348145, PMID 30384842, PMID 31570103, PMID 32518064, PMID 34226282, PMID 36260533, PMID 36849212, PMID 42173109, PMID 42712058
1RC1DK086163-01 (1), 2008 (1), R01DK061644 (1), R01DK088126 (1)